40 results about "Human cell" patented technology

This document discloses compositions for use with engineered human cells, the compositions comprising a cell regulator or a carrier encoding a cell regulator. This document describes compositions comprising engineered cells, wherein the engineered cells are engineered human cells and contain modifications that make the engineered cells more resistant to alkylating drugs or nucleoside analogs compared to non-engineered human cells. Various methods for treating diseases are provided, including methods for treating cancer in a subject by administering cell regulators and / or engineered cells as therapeutic agents.

The present application relates to the field of cosmetic technology, and more particularly to a full-link whitening and freckle-removing liposome and a preparation method thereof, the liposome comprising the following components: an aqueous phase, a membrane material and an oil phase. In the preparation process, 4-butyl resorcinol, nonapeptide-1, acetylchitosamine and ascorbic acid tetraisopalmitate are combined to form a full-link effect of signal inhibition-synthesis blockage-blocked conversion-metabolic acceleration, and a multi-target whitening and freckle-removing system is constructed. In addition, tranexamic acid, hydrolyzed yeast protein and schizophyllan are combined to synergistically make the finished product have excellent soothing and moisturizing effects. Furthermore, the finished product is prepared into a liposome capable of encapsulating active ingredients, which effectively improves the stability of the active ingredients, prevents their oxidation and inactivation, and the liposome structure is highly similar to the human cell membrane, is easy to penetrate the keratin layer gap, realizes targeted delivery to the deep layer of the epidermis, and makes the active ingredients truly act on the required site.

Provided are methods for treating pancreatic cancer with an antibody that specifically binds to human Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4).

This invention relates to the field of biosensing technology, providing a self-driven sorting device with a near-field direct-write gradient grid and its fabrication method. The invention aims to solve the problems of existing microfluidic sorting devices, such as reliance on external power, susceptibility to stacking and clogging, and severe human background interference. The device constructs a spatially heterogeneous geometric topological grid in situ on a porous substrate using a near-field direct-write process, forming a three-level gradient path consisting of a primary coarse filtration zone, a secondary sorting zone, and a tertiary retention zone. This invention utilizes substrate capillary forces to drive sample flow and achieves physical guidance and precise retention of human cells through a deterministic lateral displacement mechanism. While significantly increasing sample processing throughput, it drastically reduces the proportion of human reads in sequencing, providing a convenient and efficient technical platform for automated preprocessing of complex biological samples and high-sensitivity clinical detection.

A muscle and bone dredging instrument disclosed by the present invention comprises a host and a pole piece, the host is provided with a display screen and a host power line, the host is provided with an adjusting key, a display lamp, a plurality of keys and a wire plugging hole, the pole piece is provided with an electrode socket, one end of the electrode socket is provided with a pole needle, and the other end of the electrode socket is provided with a wire. The invention relates to the technical field of physiotherapy equipment, and the core principle is that positioning electric energy is output through a body-controlled high-energy biological electro-therapeutic apparatus and is conducted to the body of a patient by a professionally trained electro-therapist through self-adjustment of current intensity, and sine wave current matched with human body cell bioelectricity waveform is utilized to excite essence and qi to dredge the channels and collaterals, so that the body-controlled high-energy biological electro-therapeutic apparatus can be used for treating body diseases. Therefore, the treatment effect that pain is not caused by general communication is achieved.

The present invention provides siRNA, peptide oligonucleotide drugs, and their applications for suppressing the expression of the amyloid precursor protein (APP) gene in human cells. The siRNA exhibits potent activity in inhibiting APP expression. Through appropriate modifications, its ability to silence the target is enhanced while reducing off-target activity. The described siRNA and its conjugates hold promise for clinical application in the prevention and treatment of diseases associated with the APP target, including cerebral amyloid angiopathy (CAA), early-onset familial Alzheimer's disease (EOFAD), or Alzheimer's disease (AD).

The present invention relates to polypeptides, which are capable of inducing and / or enhancing secretion of IL-10 from human cells. Accordingly, the present invention provides polypeptides, which stimulate IL-10 release from human immune cells. The present invention also relates to nucleic acids encoding such polypeptide, cells expressing such polypeptide, respective pharmaceutical compositions and uses thereof.

The application discloses a traditional Chinese medicine exosome compound with anti-HPV and application thereof, and relates to the technical field of biotechnology.The compound comprises functional components secreted by a human cell co-culture system and a traditional Chinese medicine source extract, and the traditional Chinese medicine source extract is derived from a combined traditional Chinese medicine extract of Astragalus membranaceus, Isatis indigotica Fort., Honeysuckle and Sophora flavescens Ait., and relates to the technical field of biotechnology.The traditional Chinese medicine exosome carries natural active ingredients, and a multi-target anti-virus network is formed by beta-defensin-2 and interferon-gamma generated by co-culture with human cells.Compared with single traditional Chinese medicine extract or chemically synthesized nanoparticles, the HPV inhibition rate is increased by more than 170%, and the direct cytotoxicity of traditional Chinese medicine is reduced through an exosome delivery system, and the IC 50 >200ug / mL, which is significantly lower than that of a water decoction, and mucous membrane irritation experiments show no damage.

Provided are materials and methods for treating patients with hemoglobinopathies, either ex vivo or in vivo. Also provided are materials and methods for deleting and / or mutating a portion of a human beta globin locus on chromosome 11 and one or more of: a BCL11 A gene on chromosome 2, and a DNA sequence that encodes a transcriptional control region of the BCL11 A gene on chromosome 2, in a human cell by genome editing and thereby increasing the production of fetal hemoglobin (HbF) in the genome-edited human cells.

The present application specifically relates to a nucleic acid molecule encoding collagen and its use for improving hair condition. Compared with traditional direct collagen supplement, the present application has more advantages in supplementing collagen in vivo by using mRNA in vivo delivery technology (especially LNP). The technology delivers collagen mRNA instead of collagen directly into the body, promoting the human cells to produce collagen by themselves. In this way, the natural spatial structure and function of the protein are maintained, the protein activity is high, the side effects are small because it belongs to homologous substances, and long-term endogenous collagen supplement can be realized.

The present invention relates to a cell lysate wherein the lysis buffer comprises magnesium acetate, the phosphorylation inhibitor K3L, the agonist of dephosphorylation GADD34 and a caspase inhibitor for use in, or as, a cell-free system and a method for preparing a cell-free protein synthesis system. Further provided is a method for expressing a protein in the cell-free protein synthesis system, a method for screening for a candidate compound for an effect on a target molecule and a use of the cell-free protein synthesis system. The present invention also provides a kit for the above-mentioned cell-free systems.

This invention relates to T-cell receptors (TCRs) targeting the cancer / testis antigens NY-ESO-1 and CT83 presented by various HLA molecules. Preferred TCRs of this invention are derived from human T cells and exhibit high affinity and high antigen specificity both in vitro and in vivo. Furthermore, this invention also relates to the regulation of TCR-T and CAR-T cell signaling and their functional persistence in cancer immunotherapy.

The invention relates to cellular microcompartments, each microcompartment successively comprising the following layers, which are organised around at least one lumen: —at least one inner layer of human cells undergoing cardiac differentiation, expressing at least one gene chosen from PDGFRα, MESP-1, NKX2-5, GATA4, MEF2C, TBX20, ISL1 and TBX5, —at least one intermediate layer of isotonic aqueous solution, and—at least one outer hydrogel layer. The invention also relates to the cardiac tissues obtained from said microcompartments and the use thereof, particularly in the treatment of heart disease.

The present disclosure provides a method for producing and expanding a population of B cells (e.g., human B cells for clinical application). This expanded population can be used to produce a B cell vaccine containing B cells that express 4-1BBL and can promote tumor cell death.

The present application specifically relates to a nucleic acid molecule encoding collagen and its use for improving hair condition. Compared with traditional direct collagen supplement, the present application has more advantages in supplementing collagen in vivo by using mRNA in vivo delivery technology (especially LNP). The technology directly delivers collagen mRNA instead of collagen into the body, which promotes the human cells to produce collagen by themselves. In this way, the natural spatial structure and function of the protein are maintained, the protein activity is high, the side effects are small because it belongs to homologous substances, and long-term endogenous collagen supplement can be realized.

The present application relates to the technical field of medicine, in particular to a paeonia lactiflora extracellular vesicle nano-preparation for treating inflammatory diseases, which active ingredient is an extracellular vesicle extracted from paeonia lactiflora tissues.The paeonia lactiflora extracellular vesicle nano-preparation for treating inflammatory diseases, the present application uses paeonia lactiflora, a traditional medicinal plant, as the source of extracellular vesicles, successfully prepares a nano-preparation with clear activity, compared with the vesicles from animal or human cells which are currently studied more, the plant source vesicles completely avoid the risk of animal source pathogen transmission and potential immune rejection.

The present invention relates to three-dimensional (3D) tissue constructs and methods of using such 3D tissue constructs to screen for neurotoxic agents. In particular, provided herein are methods of producing and using complex, highly uniform human tissue models comprising physiologically relevant human cells, where the tissue models have the degree of sample uniformity and reproducibility required for use in quantitative high-throughput screening applications.

This invention relates to the field of human cell data analysis technology, and discloses a human cell viability data analysis system based on big data, comprising: a data acquisition module for acquiring raw experimental data and transcriptome data of human cell samples to be evaluated; a preprocessing and standardization module for preprocessing the raw experimental data and outputting a three-dimensional viability tensor; a multimodal fusion module for coupling and decomposing the three-dimensional viability tensor and transcriptome data to extract a shared sample coefficient matrix; an influence feature generation module for calculating dose-influence features, time-influence features, and viability-influence features based on the shared sample coefficient matrix and the three-dimensional viability tensor; and a prediction and interpretation module for establishing a linear regression model based on the viability-influence features and preset efficacy labels, and outputting the corresponding efficacy score for the sample to be evaluated. This invention achieves standardized integration and efficient analysis of multi-source heterogeneous human cell viability data.

The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.

A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR than can trigger T-cell activation upon detection of either CD19 or CD20 (or both). IT is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

Table linen (6), in particular disposable table linen and / or textile table linen, wherein the table linen (6) is soaked and / or impregnated with an active ingredient, wherein this active ingredient has an antiviral and / or antibacterial effect, wherein the active ingredient is an antiviral active ingredient with a biocide, in particular silver chloride and / or a chemically activated saline solution and / or a silver phosphate glass and / or a chemical-free solution at the molecular level, wherein positively charged ions are used which, upon contact, damage and / or destroy the negatively charged viral, microbial cells, and / or is silver chloride and / or titanium dioxide.and / or wherein the active ingredient has an antibacterial effect to prevent body odor and / or wherein the active ingredient prevents infection of healthy human cells by harmful viruses and / or wherein the active ingredient works with a silver and vesicle technology and / or wherein the active ingredient has positively charged nanofibers and / or wherein the active ingredient is based on a sustainable, biological, non-chemical basis and / or wherein the active ingredient is based on a specially modified water-based polymer emulsion based on special polymer mixtures, the basis of which is physical and / or mechanical in nature and / or wherein the active ingredient exhibits strong antimicrobial properties after curing,which are solely attributable to hydrophobic interactions of the cured polymer emulsion with the cell membrane of microorganisms and / or wherein this antimicrobial effect is purely physical and / or mechanical in nature and is not attributable to chemical or ionic interactions and / or wherein the polymer emulsion results in a polymer coating and / or wherein the chemical and physical properties of the polymer coating are modeled on the natural structure of microorganisms and / or wherein the active ingredient is free of biocides and nanoparticles.

A nucleic acid molecule encoding collagen and the use thereof for improving hair conditions. Compared with a traditional direct collagen supplementation, the use of an in-vivo mRNA delivery technique (especially LNPs) enables the delivery of collagen mRNA, instead of the direct delivery of collagen, into the body, thereby promoting the production of collagen by human cells. Such a method not only maintains the natural spatial structure and function of the protein, resulting in high protein activity, but also minimizes side effects due to the homologous nature of the produced substance, and further realizes long-term endogenous collagen supplementation.

This invention relates to a method for antibody reprogramming and screening based on engineered cells and its applications. This method achieves efficient in vitro rearrangement and diversity generation of antibody genes in non-lymphocytes by constructing engineered human cells containing the RAG1 / 2 recombinase system and programmable recombination signal sequence (RSS) elements. Utilizing this invention, the V(D)J rearrangement mechanism of B cells can be simulated in engineered cells, allowing for the targeted introduction of insertions, deletions, and point mutations in the antibody complementarity-determining region (CDR), resulting in a structurally diverse antibody library. Combined with piggyBac transposase-mediated genome integration, mammalian cell surface display technology, and flow cytometry sorting, high-throughput antibody screening and functional identification are achieved. This invention is simple to operate, has high antibody gene rearrangement efficiency, and produces a rich diversity of antibody libraries, making it suitable for rapid optimization of antibody drugs and discovery of new antibodies.

Non-human animals (and / or non-human cells) and methods for using said non-human animals (and / or non-human cells) are provided, said non-human animals (and / or non-human cells) having a genome containing sequences encoding human antibodies (i.e., immunoglobulin genes). The non-human animals described herein express antibodies containing immunoglobulin (Ig) light chains, said immunoglobulin light chains being characterized by the presence of a human Vλ domain. In some embodiments, the non-human animals provided herein are characterized by expressing antibodies containing a human Vλ light chain encoded by a sequence encoding a human Igλ light chain inserted into an endogenous Igκ light chain locus of said non-human animal. Methods for producing antibodies from non-human animals are also provided, said antibodies containing a human variable region and a mouse constant region.

The present invention relates to a low-sugar gochujang prepared to contain beneficial components through lactic acid bacteria, particularly postbiotics which are dead cells, while preventing the progression of additional fermentation to prevent off-flavors and overflow of contents. More specifically, the invention relates to a method for manufacturing low-sugar gochujang and low-sugar gochujang prepared using the same, wherein a substitute sugar, dietary fiber, and lactic acid bacteria (dead cells) are mixed in a predetermined ratio to maximize the beneficial components of the lactic acid bacteria, thereby enabling the consumption of said beneficial components without loss through the low-sugar gochujang, and which is characterized by the prevention of adult diseases and chronic diseases due to the low-sugar content. By manufacturing a low-sugar gochujang with a structure similar to a fermented jam or fermented spread that maximizes beneficial components and is made with low sugar, the intake of beneficial insoluble dietary fiber is enhanced, while retaining the characteristics of lactic acid bacteria (postbiotics) and preventing the overflow of contents caused by the generation of off-flavor and fermentation gas, thereby activating the immune function of normal human cells to suppress the proliferation and recurrence of cancer cells, reducing blood sugar and blood cholesterol, and improving lipid metabolism to suppress the formation and accumulation of body fat.

This invention provides a novel reprogramming strategy for constructing induced pluripotent stem cells (hiPSCs), along with its methods and applications, belonging to the field of stem cell and regenerative medicine. The method involves inducing induced pluripotent stem cells (hiPSCs) by inducing somatic cells through three stages of cell culture (Stage I, Stage II, and Stage III). This method develops an improved reprogramming strategy using human cells as raw materials. Compared to traditional methods, the new strategy incorporates an early pluripotency culture medium for 6-10 days during the reprogramming process to obtain hiPSCs. Compared to traditional methods, the hiPSCs generated by the new strategy exhibit significantly improved differentiation efficiency into mesoderm and endoderm lineages and can efficiently differentiate in vitro into functionally stable pancreatic β cells. The induced pluripotent stem cells obtained using this method provide high-quality seed cell resources for disease modeling and drug screening of organs derived from mesoderm / endoderm, showing broad application prospects.